Zoetis Inc

Zoetis Inc(ZTS)の株式分析

$79.380

+0.968 (+1.22%)終値時点

Loading chart…
高値
80.590
始値
78.290
出来高加重平均価格
79.42
出来高
5.57M
時価総額
80.52B
安値
78.290
売買代金
442.44M
EV/EBITDA(TTM)
9.25

Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including vaccines, anti-infectives, parasiticides, dermatology, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).

www.zoetis.com

AI分析 of Zoetis Inc (ZTS)

買い

Zoetis Inc (ZTS) appears to be a good buy right now, trading at $79.38 with a forward P/E of 11.99, which is attractive compared to the industry average. The stock has shown a 5-day change of +6.11%, indicating positive momentum. However, it has a significant risk with a year-to-date change of -36.96%, reflecting past volatility. Overall, the combination of a low valuation and recent insider buying trends suggests potential for recovery.

アナリスト評価(21)

上値余地 +94.26%
買い
14 買い
7 中立
0 売り
現在: 79.38
安値
130.00
平均
154.20
高値
200.00

TD Cowen

2026-08-25

目標株価

$94

買い

Stifel

2026-08-20

目標株価

$80

中立

Citi

2026-08-10

目標株価

$96

買い

Morgan Stanley

2026-08-07

目標株価

$85

買い

William Blair

2026-08-06

目標株価

—

Market Perform

バリュエーション指標

Zoetis Inc(ZTS)の現在の予想PERは11.99で、5年平均は28.07です。

予想PER

大幅な割安
5年平均 P/E
28.07
現在のP/E
11.99
割高
35.89
割安
20.24

予想EV/EBITDA

大幅な割安
5年平均 EV/EBITDA
19.82
現在のEV/EBITDA
9.25
割高
25.01
割安
14.62

予想PSR

割安
5年平均 P/S
8.08
現在のP/S
3.42
割高
10.42
割安
5.74

Alphio AI による ZTS の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%ZTS

$200.97

シナリオ価格

基

基本

基本 · 50%ZTS

$192.39

シナリオ価格

弱

弱気

弱気 · 25%ZTS

$165.91

シナリオ価格

ZTS を保有するクジラ

H

Howard Capital Management, Inc.

+ を保有ZTS

+12.71%

3か月リターン

B

Banque Pictet & Cie SA

+ を保有ZTS

+9.81%

3か月リターン

C

Carmignac Gestion SA

+ を保有ZTS

+5.97%

3か月リターン

W

W1M Asset Management Limited

+ を保有ZTS

+5.30%

3か月リターン

T

The Rockland Trust Investment Management Group

+ を保有ZTS

+5.28%

3か月リターン

L

Lazard Frères Gestion SAS

+ を保有ZTS

+4.51%

3か月リターン

イベントタイムライン

2026-10-13 (ET)

08:00:00

Zoetis Appoints Iris Knobloch to Board of Directors

2026-10-06 (ET)

08:00:00

Zoetis' Simparica Trio Outperforms NexGard Plus in Heartworm Study

2026-08-27 (ET)

12:00:00

SoftBank Plans Up to $20B Bond Offering for Refinancing

2026-08-13 (ET)

16:00:00

Zoetis' Simparica Trio Receives FDA Emergency Use Authorization

ニュース

ZTS のよくある質問 — Alphio AI が回答

Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including vaccines, anti-infectives, parasiticides, dermatology, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Zoetis Inc (ZTS) appears to be a good buy right now, trading at $79.38 with a forward P/E of 11.99, which is attractive compared to the industry average. The stock has shown a 5-day change of +6.11%, indicating positive momentum. However, it has a significant risk with a year-to-date change of -36.96%, reflecting past volatility. Overall, the combination of a low valuation and recent insider buying trends suggests potential for recovery.

21 analysts cover ZTS: 14 rate it Buy, 7 Hold and 0 Sell. The average price target is 154.20.

コミュニティ

もっと見る ↗
登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める